Biotech Research Polyphron Raises $20M in Seed Funding

The round also saw participation from Gradient, Haystack, and Compound.

The company will use the funding to build its physical and simulated systems for testing drug and therapeutic hypotheses against living human biology. It also plans to expand its tissue production from cardiac tissue to liver tissue.

What is Polyphron?

Polyphron develops artificial human biology systems designed to help drug developers test therapeutic ideas using human tissue.

The company combines AI-driven tissue manufacturing, stem-cell biology, autonomous experimental infrastructure, and AI models trained on data from living tissues.

Read More:Nevada-Based Ridgeline Raises $250M in Series E Funding

Its systems combine physical human tissue testing with simulated biology. This allows researchers to generate predictions, test them using donor-diverse human tissues, collect data, and improve the models over time.

The technology is designed to help researchers study questions such as whether a drug could cause cardiac or liver toxicity and which patients may respond to a treatment.

How Much Funding Has Polyphron Raised?

Polyphron has raised $20 million in its latest Seed financing round.

Quiet Capital led the round, with participation from Gradient, Haystack, and Compound.

The source does not provide details of previous funding rounds or the company’s total funding raised.

Who Invested in Polyphron’s Seed Round?

Quiet Capital led Polyphron’s $20 million Seed round.

Gradient, Haystack, and Compound also participated.

Why the Funding Matters

Polyphron plans to use the new funding to build its physical and simulated verification systems for testing therapeutic hypotheses against living human biology.

The company will also expand tissue production from cardiac tissue to liver tissue.

Its approach is designed to address limitations in existing drug validation methods, which can be either slow and expensive, such as clinical trials and animal studies, or less representative of human biology, such as simpler in vitro and computational systems.

Who founded Polyphron?

Polyphron was founded by Matthew Osman and Fabio Boniolo.

The source does not provide the company’s founding year or headquarters beyond New York City.

Market and Business Growth

Polyphron’s first tissue is cardiac tissue, which is currently in production across multiple donor lines at the company’s tissue foundry.

The company is onboarding a broader donor panel to capture variation in human biology.

Liver tissue is planned to follow this year, extending the company’s manufacturing, automation, and longitudinal measurement systems to drug metabolism and liver toxicity.

Polyphron’s Tissue Testing Environments combine physical and simulated human biology to study how human tissues respond to different interventions and genetic backgrounds.

What Happens Next?

Polyphron plans to expand its tissue production from cardiac to liver tissues.

The company will continue developing its automated tissue manufacturing, experimental infrastructure, and AI simulation systems to test therapeutic hypotheses against living human biology.

“AI will not cure all diseases without a verification layer. The cost of producing another new therapeutic hypothesis or intervention in many modalities could soon approach zero but this will not lead to cures until something can answer, ‘What will this intervention actually do to a heterogeneous human biological system over time?’” said Matthew Osman, Polyphron’s co-founder and CEO.

We back founder's who are building infrastructure that changes whats economically possible not just whats scientifically interesting," said Michael Bloch of Quiet Capital. If you can make tissue a manufacturable, testable unit at scale, you change the economics of drug development. Polyphron is applying that infrastructure mindset to human biology."

Read More:Insurance-Based Luzern Risk Raises $45M in Series B Funding